JAK Inhibitors as First Line Therapy in Myelofibrosis

CE / CME

Modern JAKi Strategies in Individualized Myelofibrosis Management: Considerations for First-line Therapy

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.75 Nursing contact hour

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Released: March 18, 2025

Expiration: September 17, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Case 1: Patient With Newly Diagnosed MF



  • 72-yr-old woman initially presents with shortness of breath, fatigue, significant night sweating, and weight loss

  • Assessment

    • Physical exam: Splenomegaly (12 cm below costal margin)

    • PBC: WBC count 22 x 109/L, hemoglobin 9.9 g/dL, platelets 120 x 109/L, 1% blasts

    • Biopsy: Consistent with PMF; 2+ reticulin fibrosis

    • Diagnostics: JAK2 V617F, ASXL1, and TET2 mutations



  • Not considered candidate for transplant

  • After a shared conversation, the patient has agreed with your recommendation for ruxolitinib therapy

What dose of ruxolitinib is recommended for this patient per the prescribing information?

2.

If this patient had a platelet count below 50 x 109/L, how would this change your treatment choice?